Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia

Molecular Brain Research

Volumn 121, Issue 1-2, 2004, Pages 60-69

  Mueller, Helena T ^a   Haroutunian, Vahram ^b   Davis, Kenneth L ^b   Meador Woodruff, James H ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

AMPA; Dopamine; Kainate; Neuropsychiatric disease; Neurotransmitter interactions

Indexed keywords

AMPA RECEPTOR; BIOLOGICAL MARKER; CELL PROTEIN; DOPAMINE; GLUTAMINE; IONOTROPIC RECEPTOR; KAINIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; POSTSYNAPTIC DENSITY PROTEIN 93; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEIN NF L; PROTEIN SAP102; PROTEIN YOTIAO; RECEPTOR SUBUNIT; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; MALE; MOLECULAR INTERACTION; NEUROCHEMISTRY; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN DETERMINATION; SCHIZOPHRENIA; SUBSTANTIA NIGRA;

EID: 1242283944     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molbrainres.2003.11.004     Document Type: Article

References (75)

1. Albers D.S., Weiss S.W., Iadarola M.J., Standaert D.G. Immunohistochemical localization of N-methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor subunits in the substantia nigra pars compacta of the rat. Neuroscience. 89:1999;209-220.
2. Albin R.L., Makowiec R.L., Hollingsworth Z.R., Dure L.St., Penney J.B., Young A.B. Excitatory amino acid binding sites in the basal ganglia of the rat: a quantitative autoradiographic study. Neuroscience. 46:1992;35-48.
3. Andersson O., Stenqvist A., Attersand A., von Euler G. Nucleotide sequence, genomic organization, and chromosomal localization of genes encoding the human NMDA receptor subunits NR3A and NR3B. Genomics. 78:2001;178-184.
4. Angrist B., Gershon S. Dopamine and psychotic states: preliminary remarks. Adv. Biochem. Psychopharmacol. 12:1974;211-219.
5. Angrist B., Peselow E., Rubinstein M., Corwin J., Rotrosen J. Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology (Berl.). 78:1982;128-130.
6. Bacopoulos N.C., Spokes E.G., Bird E.D., Roth R.H. Antipsychotic drug action in schizophrenic patients: effect on cortical dopamine metabolism after long-term treatment. Science. 205:1979;1405-1407.
7. Balla A., Koneru R., Smiley J., Sershen H., Javitt D.C. Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release. Neuropsychopharmacology. 25:2001;157-164.
8. Benes F.M., Todtenkopf M.S., Kostoulakos P. GluR5,6,7 subunit immunoreactivity on apical pyramidal cell dendrites in hippocampus of schizophrenics and manic depressives. Hippocampus. 11:2001;482-491.
9. Bird E.D., Spokes E.G., Barnes J., MacKay A.V., Iversen L.L., Shepherd M. Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses. Lancet. 2:1977;1157-1158.
10. Bischoff S., Barhanin J., Bettler B., Mulle C., Heinemann S. Spatial distribution of kainate receptor subunit mRNA in the mouse basal ganglia and ventral mesencephalon. J. Comp. Neurol. 379:1997;541-562.
11. Bleakman D. Kainate receptor pharmacology and physiology. Cell. Mol. Life Sci. 56:1999;558-566.
12. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. U. S. A. 94:1997;2569-2574.
13. Breier A., Adler C.M., Weisenfeld N., Su T.P., Elman I., Picken L., Malhotra A.K., Pickar D. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse. 29:1998;142-147.
14. Brenman J.E., Chao D.S., Gee S.H., McGee A.W., Craven S.E., Santillano D.R., Wu Z., Huang F., Xia H., Peters M.F., Froehner S.C., Bredt D.S. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains. Cell. 84:1996;757-767.
15. Carlsson M., Carlsson A. Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophr. Bull. 16:1990;425-432.
16. Chatha B.T., Bernard V., Streit P., Bolam J.P. Synaptic localization of ionotropic glutamate receptors in the rat substantia nigra. Neuroscience. 101:2000;1037-1051.
17. Chatterton J.E., Awobuluyi M., Premkumar L.S., Takahashi H., Talantova M., Shin Y., Cui J., Tu S., Sevarino K.A., Nakanishi N., Tong G., Lipton S.A., Zhang D. Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits. Nature. 415:2002;793-798.
18. Chen L.W., Wei L.C., Lang B., Ju G., Chan Y.S. Differential expression of AMPA receptor subunits in dopamine neurons of the rat brain: a double immunocytochemical study. Neuroscience. 106:2001;149-160.
19. Ciabarra A.M., Sullivan J.M., Gahn L.G., Pecht G., Heinemann S., Sevarino K.A. Cloning and characterization of chi-1: a developmentally regulated member of a novel class of the ionotropic glutamate receptor family. J. Neurosci. 15:1995;6498-6508.
20. Clinton S.Ma.M.-W., James H. Nucleus-specific expression of NMDA receptor associated postsynaptic density proteins in primate thalamus. Thalamus Relat. Syst. 1:2002;303-316.
21. S.M. Clinton, V. Haroutunian, K. Davis, J. Meador-Woodruff, Altered expression of NMDA receptor-associated post-synaptic density proteins in the thalamus in schizophrenia, Am. J. Psychiatry (in press).
22. Cottingham S.L., Pickar D., Shimotake T.K., Montpied P., Paul S.M., Crawley J.N. Tyrosine hydroxylase and cholecystokinin mRNA levels in the substantia nigra, ventral tegmental area, and locus ceruleus are unaffected by acute and chronic haloperidol administration. Cell. Mol. Neurobiol. 10:1990;41-50.
23. Counihan T.J., Landwehrmeyer G.B., Standaert D.G., Kosinski C.M., Scherzer C.R., Daggett L.P., Velicelebi G., Young A.B., Penney J.B. Jr. Expression of N-methyl-D-aspartate receptor subunit mRNA in the human brain: mesencephalic dopaminergic neurons. J. Comp. Neurol. 390:1998;91-101.
24. Crow T.J., Baker H.F., Cross A.J., Joseph M.H., Lofthouse R., Longden A., Owen F., Riley G.J., Glover V., Killpack W.S. Monoamine mechanisms in chronic schizophrenia: post-mortem neurochemical findings. Br. J. Psychiatry. 134:1979;249-256.
25. Das S., Sasaki Y.F., Rothe T., Premkumar L.S., Takasu M., Crandall J.E., Dikkes P., Conner D.A., Rayudu P.V., Cheung W., Chen H.S., Lipton S.A., Nakanishi N. Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A. Nature. 393:1998;377-381.
26. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry. 148:1991;1474-1486.
27. Dracheva S., Marras S.A., Elhakem S.L., Kramer F.R., Davis K.L., Haroutunian V. N-Methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am. J. Psychiatry. 158:2001;1400-1410.
28. Eastwood S.L., McDonald B., Burnet P.W., Beckwith J.P., Kerwin R.W., Harrison P.J. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Mol. Brain Res. 29:1995;211-223.
29. Farley I.J., Shannak K.S., Hornykiewicz O. Brain monoamine changes in chronic paranoid schizophrenia and their possible relation to increased dopamine receptor sensitivity. Adv. Biochem. Psychopharmacol. 21:1980;427-433.
30. Gao X.M., Sakai K., Roberts R.C., Conley R.R., Dean B., Tamminga C.A. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am. J. Psychiatry. 157:2000;1141-1149.
31. Goff D.C., Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry. 158:2001;1367-1377.
32. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience. 41:1991;1-24.
33. Grimwood S., Slater P., Deakin J.F., Hutson P.H. NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia. NeuroReport. 10:1999;461-465.
34. Harrison P.J., McLaughlin D., Kerwin R.W. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet. 337:1991;450-452.
35. Healy D.J., Haroutunian V., Powchik P., Davidson M., Davis K.L., Watson S.J., Meador-Woodruff J.H. AMPA receptor binding and subunit mRNA expression in prefrontal cortex and striatum of elderly schizophrenics. Neuropsychopharmacology. 19:1998;278-286.
36. Hollmann M., Heinemann S. Cloned glutamate receptors. Annu. Rev. Neurosci. 17:1994;31-108.
37. Humphries C., Mortimer A., Hirsch S., de Belleroche J. NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia. NeuroReport. 7:1996;2051-2055.
38. Ibrahim H.M., Hogg A.J. Jr., Healy D.J., Haroutunian V., Davis K.L., Meador-Woodruff J.H. Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am. J. Psychiatry. 157:2000;1811-1823.
39. Ichinose H., Ohye T., Fujita K., Pantucek F., Lange K., Riederer P., Nagatsu T. Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia. J. Neural Transm., Parkinson's Dis. Dement. Sect. 8:1994;149-158.
40. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
41. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1995;9-19.
42. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. U. S. A. 93:1996;9235-9240.
43. Le Corre S., Harper C.G., Lopez P., Ward P., Catts S. Increased levels of expression of an NMDARI splice variant in the superior temporal gyrus in schizophrenia. NeuroReport. 11:2000;983-986.
44. Levinson A.J., Garside S., Rosebush P.I., Mazurek M.F. Haloperidol induces persistent down-regulation of tyrosine hydroxylase immunoreactivity in substantia nigra but not ventral tegmental area in the rat. Neuroscience. 84:1998;201-211.
45. Martin L.J., Blackstone C.D., Levey A.I., Huganir R.L., Price D.L. AMPA glutamate receptor subunits are differentially distributed in rat brain. Neuroscience. 53:1993;327-358.
46. Matthysse S. Antipsychotic drug actions: a clue to the neuropathology of schizophrenia? Fed. Proc. 32:1973;200-205.
47. Meador-Woodruff J.H., Healy D.J. Glutamate receptor expression in schizophrenic brain. Brain Res. Rev. 31:2000;288-294.
48. Meador-Woodruff J.H., Damask S.P., Watson S.J. Jr. Differential expression of autoreceptors in the ascending dopamine systems of the human brain. Proc. Natl. Acad. Sci. U. S. A. 91:1994;8297-8301.
49. Meador-Woodruff J.H., Haroutunian V., Powchik P., Davidson M., Davis K.L., Watson S.J. Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. Arch. Gen. Psychiatry. 54:1997;1089-1095.
50. Meador-Woodruff J.H., Davis K.L., Haroutunian V. Abnormal kainate receptor expression in prefrontal cortex in schizophrenia. Neuropsychopharmacology. 24:2001;545-552.
51. Meador-Woodruff J.H., Hogg A.J. Jr., Smith R.E. Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder. Brain Res. Bull. 55:2001;631-640.
52. Meyer-Lindenberg A., Miletich R.S., Kohn P.D., Esposito G., Carson R.E., Quarantelli M., Weinberger D.R., Berman K.F. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat. Neurosci. 5:2002;267-271.
53. Morari M., Marti M., Sbrenna S., Fuxe K., Bianchi C., Beani L. Reciprocal dopamine-glutamate modulation of release in the basal ganglia. Neurochem. Int. 33:1998;383-397.
54. Ohnuma T., Kato H., Arai H., Faull R.L., McKenna P.J., Emson P.C. Gene expression of PSD95 in prefrontal cortex and hippocampus in schizophrenia. NeuroReport. 11:2000;3133-3137.
55. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 52:1995;998-1007.
56. Paquet M., Tremblay M., Soghomonian J.J., Smith Y. AMPA and NMDA glutamate receptor subunits in midbrain dopaminergic neurons in the squirrel monkey: an immunohistochemical and in situ hybridization study. J. Neurosci. 17:1997;1377-1396.
57. Pasinetti G.M., Morgan D.G., Johnson S.A., Millar S.L., Finch C.E. Tyrosine hydroxylase mRNA concentration in midbrain dopaminergic neurons is differentially regulated by reserpine. J. Neurochem. 55:1990;1793-1799.
58. Porter R.H., Eastwood S.L., Harrison P.J. Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Res. 751:1997;217-231.
59. Rutter A.R., Stephenson F.A. Coexpression of postsynaptic density-95 protein with NMDA receptors results in enhanced receptor expression together with a decreased sensitivity to L-glutamate. J. Neurochem. 75:2000;2501-2510.
60. Sasaki Y.F., Rothe T., Premkumar L.S., Das S., Cui J., Talantova M.V., Wong H.K., Gong X., Chan S.F., Zhang D., Nakanishi N., Sucher N.J., Lipton S.A. Characterization and comparison of the NR3A subunit of the NMDA receptor in recombinant systems and primary cortical neurons. J. Neurophysiol. 87:2002;2052-2063.
61. Sato K., Kiyama H., Tohyama M. The differential expression patterns of messenger RNAs encoding non-N-methyl-D-aspartate glutamate receptor subunits (GluR1-4) in the rat brain. Neuroscience. 52:1993;515-539.
62. Sheng M., Pak D.T. Glutamate receptor anchoring proteins and the molecular organization of excitatory synapses. Ann. N.Y. Acad. Sci. 868:1999;483-493.
63. Smith R.E., Haroutunian V., Davis K.L., Meador-Woodruff J.H. Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. Am. J. Psychiatry. 158:2001;1393-1399.
64. Smith R.E., Haroutunian V., Davis K.L., Meador-Woodruff J.H. Vesicular glutamate transporter transcript expression in the thalamus in schizophrenia. NeuroReport. 12:2001;2885-2887.
65. Snyder S.H. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am. J. Psychiatry. 133:1976;197-202.
66. Sokolov B.P. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of "neuroleptic-free" schizophrenics: evidence on reversible up-regulation by typical neuroleptics. J. Neurochem. 71:1998;2454-2464.
67. Standaert D.G., Testa C.M., Young A.B., Penney J.B. Jr. Organization of N-methyl-D-aspartate glutamate receptor gene expression in the basal ganglia of the rat. J. Comp. Neurol. 343:1994;1-16.
68. Sucher N.J., Akbarian S., Chi C.L., Leclerc C.L., Awobuluyi M., Deitcher D.L., Wu M.K., Yuan J.P., Jones E.G., Lipton S.A. Developmental and regional expression pattern of a novel NMDA receptor-like subunit (NMDAR-L) in the rodent brain. J. Neurosci. 15:1995;6509-6520.
69. Sun L., Margolis F.L., Shipley M.T., Lidow M.S. Identification of a long variant of mRNA encoding the NR3 subunit of the NMDA receptor: its regional distribution and developmental expression in the rat brain. FEBS Lett. 441:1998;392-396.
70. Takeuchi M., Hata Y., Hirao K., Toyoda A., Irie M., Takai Y. SAPAPs. A family of PSD-95/SAP90-associated proteins localized at postsynaptic density. J. Biol. Chem. 272:1997;11943-11951.
71. Toru M., Nishikawa T., Mataga N., Takashima M. Dopamine metabolism increases in post-mortem schizophrenic basal ganglia. J. Neural Transm. 54:1982;181-191.
72. Weiss-Wunder L.T., Chesselet M.F. Acute and repeated administration of fluphenazine-N-mustard alters levels of tyrosine hydroxylase mRNA in subsets of mesencephalic dopaminergic neurons. Neuroscience. 49:1992;297-305.
73. Winblad B., Bucht G., Gottfries C.G., Roos B.E. Monoamines and monoamine metabolites in brains from demented schizophrenics. Acta Psychiatr. Scand. 60:1979;17-28.
74. Wong H.K., Liu X.B., Matos M.F., Chan S.F., Perez-Otano I., Boysen M., Cui J., Nakanishi N., Trimmer J.S., Jones E.G., Lipton S.A., Sucher N.J. Temporal and regional expression of NMDA receptor subunit NR3A in the mammalian brain. J. Comp. Neurol. 450:2002;303-317.
75. Wullner U., Standaert D.G., Testa C.M., Penney J.B., Young A.B. Differential expression of kainate receptors in the basal ganglia of the developing and adult rat brain. Brain Res. 768:1997;215-223.